China Experts Consensus on Icotinib for Non-small Cell Lung Cancer Treatment (2015 version)

China Experts Consensus on Icotinib for Non-small Cell Lung Cancer Treatment (2015 version)

Bibliographic Details
Main Authors:	Yuankai SHI, Yan SUN, Cuimin DING, Ziping WANG, Changli WANG, Zheng WANG, Chong BAI, Chunxue BAI, Jifeng FENG, Xiaoqing LIU, Fang LI, Yue YANG, Yongqian SHU, Milu WU, Jianxing HE, Yiping ZHANG, Shucai ZHANG, Gongyan CHEN, Honghe LUO, Rongcheng LUO, Caicun ZHOU, Yanbin ZHOU, Qingsong PANG, Hong ZHAO, Qiong ZHAO, Aiqin GU, Yang LING, Cheng HUANG, Baohui HAN, Shunchang JIAO, Hong JIAN
Format:	Article
Language:	zho
Published:	Chinese Anti-Cancer Association; Chinese Antituberculosis Association 2015-07-01
Series:	Chinese Journal of Lung Cancer
Subjects:	Lung neoplasms
Online Access:	http://dx.doi.org/10.3779/j.issn.1009-3419.2015.07.01

Similar Items

China Experts Consensus on Icotinib for Non-small Cell Lung Cancer Treatment (2016 version)
by: Yuankai SHI, et al.
Published: (2016-07-01)

The Efficacy and Safety of Icotinib in Patients with Advanced Non-Small Cell Lung Cancer Previously Treated with Chemotherapy: A Single-Arm, Multi-Center, Prospective Study.
by: Xingsheng Hu, et al.
Published: (2015-01-01)

Clinical Observation of Icotinib Hydrochloride in First-line Therapy  for Pulmonary Adenocarcinoma
by: Xinjie YANG, et al.
Published: (2013-07-01)

Efficacy of icotinib in advanced lung squamous cell carcinoma
by: Shuai Liang, et al.
Published: (2018-09-01)

Icotinib is an active treatment of non-small-cell lung cancer: a retrospective study.
by: Xiaofeng Chen, et al.
Published: (2014-01-01)

Clinical Effects for Patients with Recurrent Advanced Non-small Cell Lung Cancer Treated with Icotinib Hydrochloride
by: Jingying NONG, et al.
Published: (2013-05-01)

Discovery of Icotinib-1,2,3-Triazole Derivatives as IDO1 Inhibitors
by: Long-fei Mao, et al.
Published: (2020-09-01)

Apatinib plus icotinib in treating advanced non-small cell lung cancer after icotinib treatment failure: a retrospective study
by: Xu J, et al.
Published: (2017-10-01)

Clinical Observation of Icotinib Hydrochloride for Advanced Non-small Cell Lung Cancer Patients with EGFR Status Identified
by: Xi LI, et al.
Published: (2015-12-01)

The Combination of Icotinib Hydrochloride and Fluzoparib Enhances the Radiosensitivity of Biliary Tract Cancer Cells
by: Zhu L, et al.
Published: (2020-11-01)

Effective treatment with icotinib in lung adenocarcinoma with EGFR and ALK co-alterations and brain metastasis
by: Ye CY, et al.
Published: (2016-10-01)

An active treatment of lung adenocarcinoma cancer with brain metastases: icotinib
by: Zhang Y, et al.
Published: (2015-06-01)

Rosacea-Like Dermatitis Caused by Icotinib Hydrochloride: A Case Report
by: Pei-Pei Liu, et al.
Published: (2019-06-01)

Efficacy and safety of icotinib in patients with brain metastases from lung adenocarcinoma
by: Xu J, et al.
Published: (2016-05-01)

Effects of icotinib on early-stage non-small-cell lung cancer as neoadjuvant treatment with different epidermal growth factor receptor phenotypes
by: Wang T, et al.
Published: (2016-03-01)

Clinical Analysis of Icotinib on Beneficiary of  Advanced Non-small Cell Lung Cancer with EGFR Common Mutation
by: Xiaowen JIANG, et al.
Published: (2016-04-01)

Outcomes of concurrent versus sequential icotinib therapy and chemotherapy in advanced non‐small cell lung cancer with sensitive EGFR mutations
by: Yun Zhang, et al.
Published: (2021-05-01)

Efficacy and safety of icotinib as first-line therapy in patients with advanced non-small-cell lung cancer
by: Shen YW, et al.
Published: (2016-02-01)

Efficacy of Icotinib Hydrochloride in the Treatment of Advanced Non-small Cell Lung Cancer
by: Xianglei Ma, et al.
Published: (2013-09-01)

Efficacy and safety of icotinib in patients with brain metastases from lung adenocarcinoma [Corrigendum]
by: Xu J, et al.
Published: (2017-03-01)

China Experts Consensus on the Diagnosis and Treatment of  Advanced Stage Primary Lung Cancer (2016 Version)
by: Yuankai SHI, et al.
Published: (2016-01-01)

Randomized Adjuvant Chemotherapy of EGFR-Mutated Non-Small Cell Lung Cancer Patients with or without Icotinib Consolidation Therapy.
by: Siyang Feng, et al.
Published: (2015-01-01)

Re-biopsy status among Chinese non-small-cell lung cancer patients who progressed after icotinib therapy
by: Wang H, et al.
Published: (2018-10-01)

The Prognostic Value of Baseline Distant Metastasis in Icotinib-Treated Patients with EGFR-Mutated Stage IV Non-Small Cell Lung Cancer
by: Wang L, et al.
Published: (2021-03-01)

Sequence-dependent synergistic cytotoxicity of icotinib and pemetrexed in human lung cancer cell lines in vitro and in vivo
by: Tianze Liu, et al.
Published: (2019-04-01)

Treating advanced non-small-cell lung cancer in Chinese patients: focus on icotinib
by: Liang JL, et al.
Published: (2014-05-01)

Characteristics of Chinese patients with cough in primary care centre
by: Bai Chunxue, et al.
Published: (2011-09-01)

Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations.
by: Wenhua Liang, et al.
Published: (2014-01-01)

Inhibition of miR-22 enhanced the efficacy of icotinib plus pemetrexed in a rat model of non-small cell lung cancer
by: Jing Zhang, et al.
Published: (2020-03-01)

Icotinib is as efficacious as gefitinib for brain metastasis of EGFR mutated non-small-cell lung cancer
by: Kejun Liu, et al.
Published: (2020-01-01)

Comparison of the inhibition potentials of icotinib and erlotinib against human UDP-glucuronosyltransferase 1A1
by: Xuewei Cheng, et al.
Published: (2017-11-01)

Efficacy of Icotinib for Advanced Non-small Cell Lung Cancer Patients with EGFR Status Identified
by: Yiping ZHANG, et al.
Published: (2013-03-01)

China Experts Consensus on the Diagnosis and Treatment of Brain Metastases of Lung Cancer (2017 version)
by: Yuankai SHI, et al.
Published: (2017-01-01)

Icotinib hydrochloride enhances chemo- and radiosensitivity by inhibiting EGFR signaling and attenuating RAD51 expression and function in Hela S3 cells
by: Wang X, et al.
Published: (2018-03-01)

Comparison of the Efficacy and Safety of Icotinib with Standard Second-line  Chemotherapy in Previously Treated Advanced Non-small Cell Lung Cancer
by: Shuyang YAO, et al.
Published: (2015-06-01)

Tricycloalternarene Analogs from a Symbiotic Fungus Aspergillus sp. D and Their Antimicrobial and Cytotoxic Effects
by: Huawei Zhang, et al.
Published: (2018-04-01)

Positive response to Icotinib in metastatic lung adenocarcinoma with acquiring EGFR Leu792H mutation after AZD9291 treatment: a case report
by: Junhui Wang, et al.
Published: (2019-02-01)

Real‐world efficacy and potential mechanism of resistance of icotinib in Asian advanced non‐small cell lung cancer with EGFR uncommon mutations: A multi‐center study
by: Lei Lei, et al.
Published: (2020-01-01)

Icotinib inhibits the proliferation of hepatocellular carcinoma cells in vitro and in vivo dependently on EGFR activation and PDL1 expression
by: Sun J, et al.
Published: (2018-11-01)

Complete remission through icotinib treatment in Non-small cell lung cancer epidermal growth factor receptor mutation patient with brain metastasis: A case report
by: Wang Tao, et al.
Published: (2016-01-01)